Condition
Non Small Cell Lung
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 4 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
4 shownA Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCCNCT07462377 · 2026-03-31
RECRUITINGA Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 MutationNCT02834936 · 2016-10-20
COMPLETEDA Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung CancerNCT00532155 · 2007-09-01
COMPLETEDClinical Impact of EUS in Staging NSCLCNCT00577746 · 2006-06-01
COMPLETEDCommon interventions
Mapped drugs appearing in these trials
Shared trial participation only; not evidence of efficacy or approval.
Leading sponsors
Trial status mix
COMPLETED3
RECRUITING1
Phase mix
PHASE11
PHASE21
PHASE31
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.